Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that it has received the “Day 74” notification from the FDA earlier than scheduled, the FDA has completed its initial…
Aerie Pharmaceuticals Submits New Drug Application For Roclatan
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, announced the submission of its New Drug Application (NDA) to the FDA for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02 percent/0.005 percent. Roclatan is a once-daily eye drop designed…
Aerie Pharmaceuticals Launches Rhopressa In The U.S.
Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that it has launched Rhopressa in the United States. Rhopressa is now in national and regional U.S. pharmaceutical distributors, and patients have access to Rhopressa through their…